Ladenburg analyst Jeffrey Cohen lowered the firm’s price target on Catheter Precision to $4.10 from $7 and keeps a Buy rating on the shares following the Q4 report. While the company’s 2023 sales was muted, it is revitalizing the sales force for LockeT with several new additions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision Q4 revenue $128,800 vs. $0 last year
- Catheter Precision to sponsor Monaco USA Arrhythmia Course
- Catheter Precision announces first use of VIVO in Qatar
- Catheter Precision announces first use of LockeT outside of U.S.
- Catheter Precision announces first use of VIVO with pediatric patient
